Drug repurposing for aging research using model organisms by Ziehm, Matthias et al.
HAL Id: hal-01787887
https://hal.archives-ouvertes.fr/hal-01787887
Submitted on 7 May 2018
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Drug repurposing for aging research using model
organisms
Matthias Ziehm, Satwant Kaur, Dobril Ivanov, Pedro Ballester, David
Marcus, Linda Partridge, Janet Thornton
To cite this version:
Matthias Ziehm, Satwant Kaur, Dobril Ivanov, Pedro Ballester, David Marcus, et al.. Drug repurpos-
ing for aging research using model organisms. Aging Cell, Wiley Open Access, 2017, 16 (5), pp.1006
- 1015. ￿10.1111/acel.12626￿. ￿hal-01787887￿
Drug repurposing for aging research using model organisms
Matthias Ziehm,1,2,† Satwant Kaur,1 Dobril K. Ivanov,1 Pedro
J. Ballester,1,‡,§,¶,†† David Marcus,1 Linda Partridge2,3 and
Janet M. Thornton1
1European Molecular Biology Laboratory, European Bioinformatics Institute
(EMBL-EBI), The Genome Campus, Hinxton, Cambridge CB10 1SD, UK
2Department of Genetics, Evolution and Environment, Institute of Healthy
Ageing, University College London, Gower Street, London WC1E 6BT, UK
3Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Str. 9b, 50931
Cologne, Germany
Summary
Many increasingly prevalent diseases share a common risk factor:
age. However, little is known about pharmaceutical interventions
against aging, despite many genes and pathways shown to be
important in the aging process and numerous studies demon-
strating that genetic interventions can lead to a healthier aging
phenotype. An important challenge is to assess the potential to
repurpose existing drugs for initial testing on model organisms,
where such experiments are possible. To this end, we present a
new approach to rank drug-like compounds with known mam-
malian targets according to their likelihood to modulate aging in
the invertebrates Caenorhabditis elegans and Drosophila. Our
approach combines information on genetic effects on aging,
orthology relationships and sequence conservation, 3D protein
structures, drug binding and bioavailability. Overall, we rank 743
different drug-like compounds for their likelihood to modulate
aging. We provide various lines of evidence for the successful
enrichment of our ranking for compounds modulating aging,
despite sparse public data suitable for validation. The top ranked
compounds are thus prime candidates for in vivo testing of their
effects on lifespan in C. elegans or Drosophila. As such, these
compounds are promising as research tools and ultimately a step
towards identifying drugs for a healthier human aging.
Key words: aging; C. elegans; computational predictions;
Drosophila; drug repurposing; lifespan.
Introduction
Age is a major risk factor for many increasingly prevalent diseases. Thus,
understanding the process of aging and finding manipulations leading to
a healthier aging phenotype are highly desirable. Many pathways shown
to be important in aging, for example the insulin/IGF-1 signalling
pathway, are also central to other biological processes and diseases, for
example cancer or diabetes. Research into these diseases is often carried
out in mammalian systems or cell lines closely related to humans. In
particular, drugs are developed mostly for humans and tested in other
mammals, where their target proteins are well characterized. Several of
these mammalian targets have orthologues in invertebrates which are
known to be involved in aging.
While model organisms closely related to humans would be ideal
from the standpoint of transferring gained knowledge, the length of
time required for observing long-term effects and changes in lifespan
and other differences in aging phenotypes are often prohibitive, for both
ethical and financial reasons. Cell cultures are not ideal because
mechanisms of cellular senescence are probably distinct from organismal
aging. Instead, aging research is often carried out in the invertebrate
model organisms Caenorhabditis elegans and Drosophila melanogaster
due to their experimentally more amenable lifespans. Thus, we propose
a method to transfer knowledge on small-molecule binding from higher
organisms, where data on compound binding are available, to lower
organisms, which are common model organisms in aging, to enable
direct testing of the compounds’ effects on longevity and aging. This first
step is almost opposite to the more common goal of transferring
knowledge from lower to higher organisms, for example in drug
discovery from mice and rats to humans. Positive effects on aging in
invertebrates would suggest drugs with potential positive effects against
human aging, which would warrant further evaluation in mammalian
models. Thus, prioritizing and testing such compounds in invertebrates
could be a first step towards drug repurposing for aging. Overall, the aim
was thus to create a list of compounds rank ordered by decreasing
likelihood of modulating aging in C. elegans and D. melanogaster,
which incorporates both likely conserved activity and targets that are
likely to ameliorate aging.
Here, we propose such a ranking procedure based on information on
genes and proteins associated with aging in different organisms,
homology and sequence conservation between them, 3D protein
structures, compound activity information and bioavailability predictions.
For each ligand, we have produced a report card describing the factors
which contribute to its score and subsequent ranking.
Results
An overview of our approach to identify and rank those ligands most
likely to affect aging in D. melanogaster and C. elegans is shown in
Fig. 1. We collected genes and proteins implicated in aging from various
sources as well as their orthologues for C. elegans, D. melanogaster,
M. musculus, R. norvegicus, H. sapiens (see Methods for details). This
resulted in a total of 13834 UniProt IDs of aging-associated proteins
(2123 in C. elegans, 1864 in D. melanogaster, 3663 in M. musculus,
1589 in R. norvegicus and 4595 in H. sapiens, for lists of these IDs see
Table S1, Supporting information). To estimate whether the compound’s
activity might be conserved between orthologues of known structure
and invertebrate target species, we examined the overall protein
conservation and especially the conservation in the binding site.
Therefore, we collected information about 3D protein structures and
drug-like molecules shown to bind them. These large data acquisition
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procedure resulted in 1480 3D protein structures with a bound drug-like
ligand. The structure–ligand complexes represent 743 different drug-like
compounds fulfilling our data requirement criteria binding to 247
different aging-associated target proteins.
Next, we proceeded to rank the ligands using properties of the
compounds and their target proteins in the model organism of interest.
We developed an empirical scoring function, with the relevant factors
multiplicatively linked. In this way, each of the factors is important and
cannot be compensated by another factor, as would be the case in an
additive scoring function. These factors include relevance to aging, the
conservation of the protein domain or domains containing the binding
site, the conservation of the binding site itself, the binding affinity and
bioavailability. The resulting base score is then modulated by the
following additional terms: drug likeness, according to Lipinski’s rule of
five, the promiscuity of the compound, its approval status as a drug and
the availability to purchase the compound. In the methods section, we
provide the reasoning, technical description and parameter values of
each factor and term.
The ranking
For D. melanogaster, 697 compounds, known to bind an aging-
associated protein or an annotated orthologue, were ranked. Com-
pounds scored between 0 (worst) and 1 (best), with a distribution shown
in Fig. 2A, with the top 15 compounds scoring above 0.91 and the top
10% scoring above 0.81. For C. elegans, 591 compounds were ranked
(Fig. 2B), with the top 15 compounds scoring above 0.56 and the top
10% scoring above 0.40 (for score distribution without the bioavailability
term see Fig. S1, Supporting information).
The overall lower scores for C. elegans as compared to D. me-
lanogaster originate from two main factors: first, the larger evolutionary
distance between C. elegans and mammals and, second, the inclusion of
the bioavailability predictions score, which is often lower than the
arbitrary bioavailability substitute used in D. melanogaster, for which
such data are not available. The bimodal distribution in D. melanogaster
is a consequence of the “aging implication“ score, which has a complex
distribution. In C. elegans, the lower bioavailability values reduce the
total scores to give a single peak. Therefore, rankings rather than
absolute scores should be compared. Table 1 shows the top 15 ranked
compounds for D. melanogaster (A) and C. elegans (B), of which six
(Fig. 3) are ranked highly in both organisms and described briefly below.
Several compounds target the same protein and a list of the top 15
compounds targeting different proteins is given in Table S2 (Supporting
information). For each compound, we provide a report card including
ranking, target protein and its conservation, a graphical representation,
images of the 3D compound-target interaction and some additional
annotations with links to relevant external resources. The full list of
compounds with their respective scores and score components for both
D. melanogaster and C. elegans and all report cards are provided in
Tables S3 and S4, Data S1 (Supporting information) and interactively
online under https://www.ebi.ac.uk/thornton-srv/software/repurposing/.
The webpage also enables the user to create tailored rankings by
excluding certain criteria or giving different weights.
The six compounds ranked highly in both organisms exemplify some
of the most promising compounds highlighted by the ranking procedure.
All six compounds are protein kinase inhibitors, many of them orally
available, approved drugs. Others are drug-like probes, not yet approved
for the clinic. Despite their common biochemical class, these compounds
target a range of different proteins associated with aging. In general,
kinases are often highly conserved between even diverse organisms
especially in the compound binding site, which the table shows are even
better conserved than the rest of the protein. These compounds rank so
highly in part because of the extensive structural work performed for
kinases, which is essential for this ranking. In contrast, structural data for
the membrane bound receptors (which are also often associated with
aging) are scarce and therefore such targets are rarely identified here.
STI, also known as imatinib or Gleevec (Fig. 3A), is an orally available
approved drug for treatment of multiple cancers, especially Philadelphia
chromosome-positive chronic myelogenous leukaemia (CML). It is a
tyrosine kinase inhibitor targeting a broad range of kinases, amongst
which ABL1 is a primary target (Fig. 4A). Human ABL1 has been
annotated to be involved in aging in GENAGE release 17 (Tacutu et al.,
2013). As kinases all belong to one family, their inhibitors often bind
more than one kinase. For example, a second target of imatinib
annotated to be involved in aging is mitogen-activated protein kinase 14
(MK14) (Fig. 4B), also known as Mpk2 or p38a in D. melanogaster,
which is annotated in UniProt with the GO term for determination of
adult lifespan (GO:008340). Additionally, there are alleles of the
C. elegans orthologue pmk-1, which are annotated as lifespan variants
in WormBase (Harris et al., 2014). The imatinib binding sites on ABL1
and on MK14 are very well conserved between human and the
invertebrates, suggesting a good chance of conserved binding. Addi-
tionally, a predicted maximal binding affinity of 100 nM, in mammals, is
relatively strong, and for C. elegans, the bioavailability prediction
indicates very likely successful bioaccumulation in the worm.
NIL, also known as nilotinib or Nexavar (Fig. 3B), is an orally available
approved drug for treatment of imatinib-resistant CML. Like imatinib, it
is an inhibitor targeting a broad range of kinases including ABL1.
Nilotinib also binds to mitogen-activated protein kinase 11 (MK11), while
Fig. 1 Schematic of principal steps in data gathering and filtering (with number of
proteins, structures and drug-like compounds) and the use of these data in
determining the components of the ranking procedure. The ranking properties are
calculated per model organisms.
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imatinib binds to MK14. As MK11 and MK14 are closely related, MK11’s
role in aging is implied through the UniProt annotation of the common
D. melanogaster orthologue Mpk2. Nilotinib has a stronger predicted
binding affinity (23 nM) than imatinib and a similarly good predicted
bioavailability in C. elegans. However, nilotinib violates two of the
Lipinski rules, resulting in a slightly lower ranking compared to imatinib.
BAX, or sorafenib (Fig. 3C), is another orally available, approved drug
for treatment of different cancers, including advanced renal cell
carcinoma. Sorafenib is a tyrosine kinase inhibitor of several targets
including the Raf kinases and MK14. While the binding site of Sorafenib
on MK14 is partly overlapping with that of imatinib, it makes contact
with four more amino acids and has a similarly strong predicted binding
affinity (35 nM). However, this is contrasted by less favourable, albeit still
reasonable, predicted bioavailability in C. elegans and one violated
Lipinski rule.
TAK, also known as dorsomorphin (Fig. 3D) or compound C, is not an
approved drug, but an experimental compound (as listed in DrugBank)
and available from a number of vendors. Dorsomorphin has been shown
to inhibit bone morphogenetic protein (BMP) signalling, causing cancer
initiating cells to lose some stem-cell-like features and induce a
proliferation-like process (Garulli et al., 2014). Dorsomorphin has also
been shown to inhibit AMP-activated protein kinase catalytic subunit
alpha-2 (Handa et al., 2011; Fig. 4C), which is known as AMPKa or
SNF1A in D. melanogaster and as aak-2 in C. elegans. AMPK is a well-
known intracellular energy sensor, involved in the target-of-rapamycin
(TOR) signalling pathway. It has also been shown to be involved in aging
in a multitude of experiments in different organism. The binding site is
completely conserved between human and D. melanogaster and con-
tains only one changed amino acid (Y2H) in C. elegans. The predicted
binding affinity (63 nM) is quite strong, while the predicted bioavailability
for C. elegans is only moderate, and no additional information about
oral availability is present.
GVP (Fig. 3E) is classified by DrugBank as an experimental antineo-
plastic agent and commercially available. It inhibits RAC-beta serine/
threonine–protein kinase, also known as AKT2 or protein kinase B beta
(Fig. 4D), which is a part of the insulin/IGF-1 and TOR signalling
pathways. The C. elegans orthologue akt-2 is annotated in UniProt with
the term determination of adult lifespan (GO:008340). More specifically,
RNAi inhibition of Akt in D. melanogaster and akt-1 and akt-2 in
C. elegans extends lifespan (Tullet et al., 2008; Biteau et al., 2010). The
binding site contains 4–5 conservative changes (91% similarity between
human and either invertebrate). The predicted binding affinity (23 nM) is
quite strong, with reasonable predicted bioavailability for C. elegans.
Finally, JNF (Fig. 3F) is also an experimental compound listed in
DrugBank and commercially available. It is a kinase inhibitor targeting
the mitogen-activated protein kinase 10 (MK10) (Fig. 4E), whose
C. elegans orthologue jnk-1 is annotated in UniProt with the GO term
“determination of adult lifespan”. More specifically, moderate RNAi of
the D. melanogaster orthologue Bsk in adult animals extended lifespan,
while mutants of C. elegans jnk-1 exhibited decreased lifespan (Oh
et al., 2005; Biteau et al., 2010). The reasons for the different lifespan
effects, besides possible organismal differences, are likely to be a
detrimental developmental effect in C. elegans jnk-1 mutants as well as
a likely dosage dependency of the effect of modulating MK10. The
predicted binding affinity is relatively strong (120 nM); however, the
predicted bioavailability in C. elegans is significantly lower than for the
other compounds described above.
Overall, these six compounds exemplify the promising candidates for
modulating lifespan in both D. melanogaster and C. elegans highlighted
by the ranking procedure.
Evaluating the ranking
Modelling and docking
In the above high-throughput approach, binding of the compounds to
the model organism proteins is estimated indirectly, through conserva-
tion of sequence. Here, we tested this assumption further by modelling
the orthologues in D. melanogaster and C. elegans for one hit (com-
pound P37 to human MK14) and docking the compound directly. P37 is
a compound classified by DrugBank as experimental and does not violate
any of the Lipinski rules. Its structure was determined by X-ray
crystallography in complex with human MK14 at 2.10A (PDB:3GFE,
Wurz et al., 2009). The closest homologues in D. melanogaster and
C. elegans include p38a and pmk-1, respectively, which are 67% and
61% identical. We successfully modelled the protein structures of the
homologues having removed the P37 ligand before modelling, not to
bias the modelling procedure. P37 was docked into the two models, and
their binding affinity was predicted 7.65 log Kd/Ki (D. melanogaster),
7.90 log Kd/Ki (C. elegans). This affinity was very similar to that
predicted from the structure of the human complex: 7.75 log Kd/Ki
(Human). This is also evident from a superposition of the binding sites of
human crystal structure and D. melanogaster or C. elegans protein
structure model (Fig. 5). The structurally determined conservation in
binding is in very good agreement with the sequence-based binding-site
conservation score of 0.951 (D. melanogaster) and 0.914 (C. elegans)
using the 3D information only to determine the amino acids in contact
with the ligand.
Literature mining for the top ranked compounds
We conducted a thorough literature search for articles examining any of
the top 25 ranked compounds with respect to lifespan effects. Searching
the PubMed database with the compound names and their synonyms in
combination with aging keywords and terms for C. elegans and
D. melanogaster resulted in 38 hits. Querying the PubMed Central
database of full-text articles resulted in 473 relevant hits of which only
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four publications describe relevant lifespan experiments, with variable
results.
Liu et al. (2011) tested Sorafenib (BAX), for effects in Parkinson’s
models in C. elegans and D. melanogaster. They reported that sorafenib
at 1 and 10 lM increased survival and reduced locomotor impairment in
ddc-GAL4; UAS-G2019S-LRRK2 flies, while none of the concentrations
tested was reported to alter lifespan of controls. Furthermore, C. elegans
treated with Sorafenib showed positive effects on neuronal survival,
while overall lifespan was reported unchanged. However, this study tried
to exclude effects from cellular processes associated with aging, stating
“these effects were maintained to a minimum in our studies” (Liu et al.,
2011).
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Fig. 3 Molecular structures of top overlapping chemical compounds. (A) STI or imatinib (B) NIL or nilotinib (C) BAX or sorafenib (D) TAK or dorsomorphin/compound c (E)
GVP (F) JNF.
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Fig. 4 Binding sites of top overlapping compounds. (A) STI or imatinib binding to human tyrosine kinase ABL1 (B) STI or imatinib binding to human mitogen-activated
protein kinase 14 (MK14).(C) TAK or dorsomorphin binding to AMP-activated protein kinase catalytic subunit alpha-2 (D) GVP binding to RAC-beta serine/threonine–protein
kinase AKT2 (E) JNF binding to mitogen-activated protein kinase 10, also known as JNK3.
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Yang et al. (2015) evaluated the effect of b-guanidinopropionic acid
and dorsomorphin (TAK) on wild-type D. melanogaster lifespan. While
the effect of dorsomorphin on wild-type flies was not discussed, the
survival curves showed, probably significant, lifespan shortening, which
is in line with what would be expected by inhibiting AMPK and confirms
the lifespan changing effects of one of our top ranked compounds.
The third publication tested the lifespan effect of genistein (40,5,7-
trihydroxyisoflavone) in C. elegans. While genistein is not in our list of
compounds, it was found because the highly similar compound 3’,4’,7-
trihydroxyisoflavone (PDB HET code: 47X) is ranked 21st in C. elegans
(for comparison of binding of 47X and genistein see Fig. S2, Supporting
information). It remains unclear how similar their biological effect is, but
Lee et al. (2015) report genistein to significantly increase lifespan and
stress tolerance of wild-type C. elegans lifespan at 50 and 100 lM
concentrations.
Finally, Wilson et al. (2008) reported modest, albeit not significant,
beneficial effects (15% increased median lifespan) in C. elegans with
piceatannol (PDB HET code: P01, ranked 73rd in C. elegans). P01 binds to
ribosomal protein S6 kinase alpha-1, whose binding site is completely
conserved between human and invertebrates.
Rapamycin
Of the well-known drugs examined for their effect on lifespan in
invertebrates, only rapamycin (PDB HET code: RAP) is included in our
ranking due to the data requirements. Rapamycin was shown to extend
lifespan in many organisms including C. elegans, where it is ranked,
however, only 395th according to the method presented here. This is
because rapamycin violates three of the four Lipinski rules as well as
being predicted by the Burns et al. (2010) methodology to have low
bioavailability in C. elegans. Furthermore, four of the ten amino acids
forming the binding site on TOR are not conserved between human and
C. elegans. However, rapamycin has a highly unusual mode of action of
disrupting a protein–protein interaction between TOR and FKBP and thus
also unusual properties. If rapamycin had a bioavailability score of 0.9,
instead of 0.2 it would rank 16th in C. elegans, clearly demonstrating
the impact of bioavailability. In D. melanogaster, with no bioavailability
prediction available, rapamycin ranks 95th, classifying it as a promising
compound. A different promising kinase inhibitor PI-103 (PDB HET code:
X6K), also targeting TOR, is, however, ranked 5th in C. elegans and 17th
in D. melanogaster. In contrast to rapamycin, PI-103/X6K has no
violations of Lipinski’s rules for likely drugs, a high predicted bioavail-
ability in C. elegans, a completely conserved binding site in both
invertebrate species and high predicted binding affinity. While our
ranking only considered the effect on TOR, PI-103/X6K also inhibits
phosphoinositide 3-kinase (PI3K), which is also strongly associated with
aging (Fan et al., 2006), suggesting that it is a promising candidate for
trials.
Unbiased C. elegans lifespan screen
Finally, we found a single unbiased screen of a set of compounds for
effects on lifespan in C. elegans where complete experimental results
are reported. The study by Ye et al. (2014) tested the library of
pharmacologically active compounds (LOPAC), comprising 1280 differ-
ent compounds at a fixed concentration of 33 lM in liquid culture. Of
these compounds, only four were included in our C. elegans ranking,
ranking 220th or lower in our calculations. None of them significantly
affected lifespan (P ≥ 0.05) according to Ye et al. (2014). Furthermore,
15 of the compounds tested are included in our D. melanogaster
ranking (the 11 additional compounds had no annotated C. elegans
orthologues in Compara and thus could not be ranked in C. elegans).
Three (B43, STR and TCD) of the 15 compounds are reported to
significantly affect lifespan (P < 0.05; B43 extends and STR and TCD
shorten lifespan), these include the two highest ranked of this list. This is
a significant enrichment for lifespan changing compounds by rank
(hypergeometric test P < 0.03 for overlap of lifespan extending com-
pounds with compounds ranked in the top 250 of the overall list).
Discussion
In this proof-of-principle study, we show that, by combining different
types of information, it is possible to create a ranked list of compounds
with respect to their likelihood to modulate aging in invertebrates. The
ranking demonstrated strong differences between potential candidates
for compound testing compared to random selection of any compound
binding an orthologue of a known modulator of aging.
The pipeline developed is fast and conservative, choosing to focus on
those compounds with strongest supporting evidence for an effect on
aging. The pipeline could be “relaxed“ to include more distant
orthologues or compounds and proteins without any human complex
structural data. Furthermore, the ranking procedure presented here also
serves as a blueprint for similar approaches, where individual factors or
terms can be omitted or substituted with alternative methods of
preference. It is interesting that most of the drugs at the top of the list
were developed to target cancers, perhaps reflecting the increased
occurrence of cancer with age.
Although no direct experimental validation is available, we provide
various lines of evidence indicating the success of the ranking and
making the top ranked compounds interesting candidates for
Fig. 5 Interaction between the
superimposed P37 ligand and the amino
acids in the active binding site (A) in human
(orange and pink) and D. melanogaster
(grey and blue) (B) in human (orange and
pink) and C. elegans (grey and blue).
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experimental in vivo testing. Due to uncertainty about compound
dosage, such experiments would require testing at multiple concentra-
tions, for example three concentrations spanning three orders of
magnitude. In C. elegans, the use of a specific drug-sensitive mutant
strain (partial loss-of-function bus-8 mutant) has been suggested for
drug screening (Partridge et al., 2008). A complication in C. elegans
drug screening can be the live E. coli bacteria contained in the most
commonly used food, which might metabolize compounds (Cabreiro
et al., 2013; Zheng et al., 2013).
Two recently published studies also aim to prioritize possible
compounds against aging using alternative computational approaches.
Calvert et al. (2016) use similarity of gene expression profiles caused by
compounds in human cell lines to those observed for a rat caloric
restriction model as prioritization criteria for C. elegans, while Snell et al.
(2016) employed a ligand homology modelling approach on individual
proteins to prioritize compounds for testing in Rotifers. Both approaches,
however, do not consider interspecies differences and bioavailability
constraints, which are critical.
Pharmacological interventions can be an extremely helpful research
tool, which enable time-restricted intervention in a dosage dependent
way, thereby allowing a more precise control than genetic interventions.
Furthermore, various compounds can be easily administered in combi-
nation and further combined with established genetic or environmental
intervention. As such, pharmacological interventions are an orthogonal
manipulation system which will help to further deconvolute the
pathways and processes relevant to aging. The recently established
Caenorhabditis Intervention Testing Program (CITP) for robustly testing
pharmacological interventions for their effect on aging across different
Caenorhabditis strains and species further demonstrates the relevance
and timeliness of our computational ranking procedure.
Neither C. elegans nor D. melanogaster are typical model organisms
for pharmaceutical research, but successful examples in drug screenings
exist (Desalermos et al., 2011, Pandey & Nichols, 2011) and demonstrate
the feasibility of large-scale compound screens. Clearly, successful
evaluation of compounds against aging in either invertebrate model
would require subsequent testing in mammalian models, for example in
the National Institute on Aging Interventions Testing Program (Warner
et al., 2000), in order to determine the most likely compounds to
influence human aging.
Experimental procedures
Data sources and mapping
Genes and proteins associated with aging were obtained from the
GENAGE database (Tacutu et al., 2013) as well as from general databases
(UniProt (UniProt Consortium 2014) and Ensembl (Flicek et al., 2014))
and organism-specific databases (RGD (Dwinell et al., 2009), MGI (Eppig
et al., 2012), FlyBase (St Pierre et al., 2014) and WormBase (Harris et al.,
2014)) using the Gene Ontology term for aging (GO:0007568). We
considered five selected species of interest: C. elegans, D. melanogaster,
M. musculus, R. norvegicus and H. sapiens. All results were mapped to
the corresponding Ensembl and UniProt entries, and all entries were
cross-mapped between Ensembl and UniProt. For each gene/protein
associated with aging, all orthologues in the five species were identified
using Ensembl Compara. PDB codes corresponding to these proteins
were retrieved from UniProt, Ensembl and the PDBsum database (de
Beer et al., 2014). DrugBank IDs (Law et al., 2014) and ChEMBL IDs
(Gaulton et al., 2012; release 15) of compounds binding aging-
associated proteins were collected from UniProt, PDBsum and ChEMBL.
Compound IDs were cross-referenced with UniChem (Chambers et al.,
2013) and, where possible, mapped to the ZINC (Irwin et al., 2012) and
eMolecules databases (http://www.emolecules.com/) of commercially
available compounds, ChEBI (Hastings et al., 2013) and to PDB HET
codes, the compound identifiers used in PDB structures. PDB HET codes
were used to identify PDB files of aging-associated proteins with bound
drug-like ligands of the DrugBank and ChEMBL set and at least one
orthologue in C. elegans or D. melanogaster. All targets with no
homologue in C. elegans or D. melanogaster were filtered out, because
these are the target species. Additionally, for each homologue family
and species, only the homologues with the smallest number of gaps in
the binding site and the highest binding-site identity or similarity were
kept.
The ranking score equations and components
The ranking score is a bounded score between zero and one determined
by five multiplicative factors and four additional terms for bonuses and
losses, defined by the following formula:
Ranking score ¼ max ðmin ðAging implication Domain conservation
 Binding-site conservation Binding affinity
 Bioavailabilityþ Lipinski lossþ Promiscuity loss
þ Availability to purchase bonusþ Approveddrug
bonus; 1Þ;0Þ:
Aging implication
This factor represents the certainty of our knowledge associating the
protein target with aging. It is derived from the Gene Ontology
(Ashburner et al., 2000) annotation evidence codes. A distribution of
scores for this and the other terms are available online under https://
www.ebi.ac.uk/thornton-srv/software/repurposing/.
Aging implication ¼ ð1 ðGO evidence scoreþ 0:1 identifier
mappingsÞÞ2
GOevidence score
¼
0:01or 0:02 Experimental EvidenceCodes
0:15
0:16
0:28or 0:29
ComputationalAnalysis EvidenceCodes
AuthororCurator Statement
Automatically assignedorNo -biol.DataorNotRecorded
8>><
>>:
Genes implied through being listed in GenAge are assigned a GO
evidence score of 0.01.
Protein domain conservation
This factor and the factor for binding-site conservation represent the
requirements for conservation to maintain binding of the compound to
the protein target. In practice, we use a conservation score for the
protein domains, which contain the binding-site contacts. A multiple
sequence alignment (MSA) of the amino acid sequence from the 3D
structure, the corresponding UniProt entries and their homologues in the
five species of interest was constructed using MAFFT with maxiterate
1000 and localpair options (Katoh & Toh, 2008). Pairwise sequence
identity between the protein of known structure and each homologue,
as well as the pairwise Grantham-based similarity (Grantham, 1974), was
calculated. Grantham-based similarity was defined as
1 Grantham Distance215 , resulting in a 0 to 1 scaled similarity measure.
Values for amino acid codes B, Z and X were calculated as average of the
D and N, Q and E and all amino acids, respectively (for Grantham-based
similarity matrix see Data S2, Supporting information). We used protein
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domain assignments from Gene3D (Lees et al., 2014) for the UniProt of
the 3D structure. All domains in contact with the bound ligand where
jointly considered. For amino acids contacts, which lay outside annotated
domains, we used a window of 50 amino acids around the contact
instead.
Domain conservation ¼ logistic (Grantham-based similarity of domain
sequence, 0.6, 0.1).
The logistic transformation, logisticðx; l; sÞ ¼ 1
1þexþl=s, was applied,
because differences in medium similarities are more important than
equally large differences amongst very low or very high percentage
similarities. For compounds binding to more than one protein, the
maximum values for domain conservation, binding-site conservation and
binding affinity were used.
Binding-site conservation
This factor represents the conservation in the binding site, which is
especially important for conserved activity of the compound. We
obtained the amino acid positions from the MSA that are in contact
with the bound ligand as indicated in PDBsum. As we observed that a
large majority of binding sites contained more than 50% identical amino
acid residues, we based this factor on the Grantham-based similarity
score of 50% most dissimilar positions only, to increase sensitivity of the
factor.
Binding-site conservation ¼ Grantham-based similarity of 50% most
dissimilar binding-site residues.
Binding affinity
While all compounds ranked are shown to bind their target, as evident
from a ligand–protein complex structure, the binding affinity of the
interaction can range from low to high. Clearly, a compound binding
only with millimolar affinity (103 M) to a target is less desirable than a
compound binding with nanomolar affinity (109 M) for any given
target. In our work we therefore assume that higher starting affinities
also predict a better chance of binding to slightly altered targets. This
factor represents the binding affinity and is derived from the log-binding
affinity predicted by RF-Score v2 (Ballester et al., 2014) based on the
protein–ligand complex structure in 3D. Predicted binding affinities were
used because measured binding affinities were not available for all
complexes and previous validation demonstrated the high accuracy of
RF-Score at this task (Ain et al., 2015). As RF-Score v2 required input
files in PDBbind format, but not all complexes of interest were in the
PDBbind database (Wang et al., 2004), we created and successfully
tested a PDBbind format mimicking pipeline (see Data S3, Supporting
information).
Binding affinity = logistic(RFScore, 5, 1).
Bioavailability
In order for any compound to be able to exert an effect, it needs be able
to interact with its, mostly intracellular, targets. Thus, bioavailability is an
essential prerequisite. In C. elegans, bioavailability has been found to be
very limited (<10%) in standard approaches (Burns et al., 2010). After
evaluating the only published bioavailability predictor for C. elegans
(Burns et al., 2010) for its predictive performance (for details see Data
S3, Supporting information), we used its score logistically transformed
and scaled as a basis for our bioavailability score in C. elegans. As we
could not successfully evaluate the relevance or suitability of the
predictor for D. melanogaster, we opted not to use these predictions in
the D. melanogaster ranking, but rather substitute the bioavailability
score with a fixed term, which can be readily replaced when predictions
or measurements of bioavailability in D. melanogaster become available.
Bioavailability
¼ logistic Burns score;4;2:25ð Þ  0:8þ 0:2 C: elegans
0:9 D:melanogaster

The modulating losses and bonuses are defined as follows.
Lipinski score
This term is one of four terms representing nonessential beneficial and
detrimental properties. This term has been used to represent the drug
likeness based on Lipinski’s rule of five (Lipinski et al., 2001), which has
been widely applied in drug development processes. This rule of thumb
states that compounds have a high likelihood of being orally active in
humans if they have a molecular weight less than 500 Daltons, an
octanol–water partition coefficient log P of no more than 5, no more
than 5 hydrogen-bond donors and no more than 10 hydrogen-bond
acceptors. This and the following terms are scaled to modulate the
overall score.
Lipinski loss ¼ #violations of Lipinski
;s rule of five
20
Binding promiscuity
An examination of the list of compounds and their targets showed a few
compounds, which are found to bind to a large number of targets. These
compounds included well-known omnipresent metabolites such as ATP,
but also compounds often used to aid crystallization processes, such as
PEG. These highly promiscuous compounds are less interesting com-
pared to more specific compounds targeting one or a few targets. This
term penalizes compounds by number of targets.
Promiscuity loss
¼ logisticð#different aging-related proteins crystallized with;7;1Þ
5
Availability to purchase
The final two terms of the ranking are not requirements for the
successful modulation of aging, but influence the ease of performing
any experiments and taking positive results forward. This term gives a
bonus for purchasable compounds, which is a requirement for most
researchers to examine its effects, as few will have the means to
synthesize any desired compounds.
Availability to purchase bonus
¼ 0:1 if contained in ZINC or eMolecules database
0 else

Drug approval status
Finally, approved human drugs and drug candidates (as defined in
DrugBank Law et al., 2014) receive a bonus. These compounds would
be especially attractive if found to extend lifespan in model organisms
because they have already been shown to be tolerated by humans at
least under certain circumstances. Thus, they might offer shorter
development routes to beneficial interventions against human aging
by drug repurposing.
Approveddrugbonus
¼
0:1 ifdesignatedasknowndrug inChEMBL
0:075
0
ifnotdesignateddrug inChEMBL,but contained inDrugBank
else
8<
:
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Protein structure modelling and docking
Single template modelling was performed using Automodel and loop
modelling from MODELLER 9.13 (Eswar et al., 2006). Trailing amino acid
residues lacking structural information and the P37 ligand were removed
before modelling, while other hetero atoms such as ions were included.
The best model was selected based on discrete optimized protein energy
(DOPE) using the CHARM22 force field and root-mean-square deviation
(RMSD). Rigid-protein, flexible-ligand docking experiments were per-
formed using AUTODOCK vina4.2 (Trott & Olson, 2010) with a 27.5 A
search box. Finally, protein structure model files with docked ligand were
converted to PDBbind mimicking files for RF-Score binding affinity
prediction.
Literature mining
Literature mining was performed by querying PubMed and PubMed
Central (NCBI Resource Coordinators 2015) using the NCBI Entrez
Programming Utilities (eUtils; http://eutils.ncbi.nlm.nih.gov/entrez/eutils).
We created search term dictionaries for compound names and
synonyms, lifespan terms and species terms, with all combinations of a
drug dictionary term, a survival dictionary term and a species term. The
query was conducted to use the automatic term expansion (PubMed),
which, for example, expanded “ageing” to “(aging[MeSH Term] OR
aging[All Fields] OR ageing[All Fields])”, or manual equivalent expansion
(PubMed Central). The compound dictionary was constructed to contain
for each of the top 25 compounds for D. melanogaster and C. elegans:
the ChEMBL, DrugBank and ZINC identifiers if available, all names and
synonyms listed by these three resources as well as all names from the
NCI/CADD Chemical Identifier Resolver (http://cactus.nci.nih.gov/che
mical/structure). Names shorter than three characters were excluded.
The survival dictionary comprised “longevity”, “lifespan”, “life-span”,
“life span”, “life history”, “survival”, “mortality”, “ageing” and the
species dictionary included “Drosophila melanogaster”, “Drosophila”,
“melanogaster”, “Caenorhabditis”, “elegans”, “Caenorhabditis ele-
gans.” The dictionaries were constructed to be relatively promiscuous
in order not to miss any relevant publications. For the PubMed Central
queries, the survival dictionary did not contain “ageing”, but all queries
had the additional constraint “+AND+(aging[MH]+OR+aging
[ARTICLE]+OR+ageing[ARTICLE])” to gear the results more towards
longevity experiments in contrast to cancer survival. To avoid finding
articles where the relevant terms are only part of the references, we
restricted the survival and species terms, but not the compound term, to
the article body. For all PubMed and PubMed Central queries, all space
characters were substituted with “+” as required by the query tool.
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